|
It's 'Round To It' Time ~
Sunday, July 19, 2026
Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
Home Health and AI Stocks Among Picks Trading Under Ten Dollars
|
Skip Headlines Straight to Original Research
Hi there,
Our investment research analysts are going to be releasing their next investment idea tomorrow morning, around 10:00 AM Eastern time.
It will be first sent to subscribers that sign up to receive American Market News via SMS, then later in the morning to people who subscribe to our email newsletter or read our content on our website.
Don't miss out on your opportunity to be among the first to see our next stock idea. Our last idea was quite popular with our subscribers.
Get Tomorrow Morning's Stock Idea
Jessica Mitacek
Managing Editor
American Market News
Exclusive Story from MarketBeat Media
Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump
Submitted by Chris Markoch. Article Published: 7/9/2026.
Key Points
- Constellation Brands topped revenue expectations but missed on adjusted EPS in its fiscal 2027 first-quarter report, even as the stock trades near multi-year lows.
- The beer segment, led by Modelo Especial and Corona Extra, kept growing while Wine and Spirits posted strong organic sales gains despite a large reported decline tied to a divestiture.
- New CEO Nicholas Fink outlined an occasion-based growth strategy as the company continued returning cash to shareholders through buybacks and dividends amid raised full-year guidance.
- Special Report: The company SpaceX cannot operate without
Constellation Brands (NYSE: STZ) reported its fiscal year 2027 first-quarter results on June 30, and the results were mixed. Revenue of $2.43 billion topped expectations of $2.39 billion. However, Constellation missed on the bottom line, reporting adjusted earnings per share (EPS) of $3.43, below the $3.70 estimate.
Even so, earnings were higher year over year (YOY). Management also raised its full-year reported EPS outlook to $11.50 to $12.20 and reaffirmed comparable guidance of $11.20 to $11.90. At the midpoint, reported EPS would be 23% higher YOY.
[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker included (Ad)
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.
That hasn’t done much to satisfy investors. As of the market close on July 8, STZ continued to trade near multi-year lows around $130, leaving shares below their 200-day moving average of roughly $146. The stock's MACD also remains in negative territory.
When it comes to earnings reports, investors often focus too much on what the company just did and not enough on its future outlook. In the case of Constellation Brands, that’s a disconnect worth examining, especially since STZ is trading approximately 29% below the analysts’ consensus price target of $167.89.
Constellation's Beer Business Continues to Drive Growth
Constellation's beer segment, anchored by Modelo Especial and Corona Extra, grew net sales 2% on a 1.8% increase in shipment volumes. Operating margin held roughly flat at 39%. Depletions, a measure of what's actually moving off store shelves, dipped by a modest 0.3%. The company remained the top dollar-share gainer in the U.S. beer category during the quarter, with five of the 15 top share-gaining brands nationally.
Wine and Spirits told a more complicated story. Reported net sales fell 47%, but that decline was almost entirely due to last year's divestiture of a large portion of the mainstream wine portfolio. Strip that out, and organic net sales actually grew 8%, with depletions up 6.6%. The Kim Crawford brand’s depletions grew by roughly 4%, while Mi CAMPO Tequila surged 62%. The segment's operating loss narrowed sharply, improving 140 basis points to a margin of negative 0.7%.
Constellation Challenges the GLP-1 Bear Case
A popular bear thesis for beer and wine stocks holds that GLP-1 weight-loss drugs are suppressing overall drinking. Constellation's numbers argue against that story, at least for now. If GLP-1 adoption were driving a broad pullback in alcohol consumption, beer volumes should be falling alongside wine and spirits. Instead, beer shipments grew, and organic sales and depletions for wine and spirits both increased.
This suggests that Constellation Brands is adjusting to changing consumer tastes. That's different from a company stuck in a doom loop of declining demand.
What stands out in the numbers is lower pressure on the income ladder. Management described a "discerning and value-conscious consumer mindset," particularly among lower-income households, as gas prices rose more than 50% nationally during the quarter.
That's the K-shaped economy playing out in real time: a bifurcated consumer base, with higher-end brands that have strong equity, like Modelo and Kim Crawford, continuing to find buyers even as lower-income households pull back elsewhere.
Constellation Rewards Shareholders With Buybacks and Dividends
Constellation returned over $400 million to shareholders during the quarter. That was split between $324 million in year-to-date share repurchases and a quarterly dividend of $1.03 per share. Management is targeting a comparable net leverage ratio of approximately 3x while continuing to fund the construction of a third brewery in Veracruz, Mexico. Operating cash flow rose 4% to $662 million, and free cash flow increased 9% to $485 million.
New CEO Nicholas Fink Outlines Constellation's Growth Strategy
This was the first earnings report with Nicholas Fink as President and Chief Executive Officer (CEO). Fink used the earnings commentary to outline an occasion-based growth strategy. The plan centers on understanding when, where, and why consumers choose specific brands, rather than treating growth purely as a distribution or pricing exercise.
Fink singled out Modelo Especial's continued distribution runway and relatively low brand awareness as a specific opportunity, alongside continued investment in fast-growing Pacifico and Mi CAMPO.
Constellation Stock Offers Value for Patient Investors
At roughly 11x earnings, Constellation trades at a discount that looks reasonable for a defensive consumer name with a dominant beer franchise and an improving wine-and-spirits business. The stock's continued technical weakness suggests the market hasn't fully priced in the operating improvement yet.
To be fair, risks remain. Wine and Spirits still operates near breakeven, tariff exposure on agricultural inputs remains an ongoing concern the company flags directly in its filings, and the broader beverage alcohol category faces real questions about long-term consumption trends.
But this quarter's results suggest the pressure so far is more about consumer selectivity than a structural retreat from alcohol altogether. For patient investors, Constellation's combination of earnings growth, aggressive capital returns, and a still-skeptical stock chart is worth watching closely.
Exclusive Story from MarketBeat Media
3 Small-Cap Stocks Trading Under $10 With Room to Run
Submitted by Bridget Bennett. Article Published: 7/15/2026.
Key Points
- As mega-cap tech stumbles, analyst James Early recommends Aveanna Healthcare, Genworth Financial, and eGain Corporation as profitable small caps trading under $10 per share.
- Aveanna benefits from insurer demand for home health care, Genworth's mortgage insurance unit offsets a legacy long-term care drag, and eGain is repositioning around AI customer service.
- Despite the appeal of retail investors having an edge over institutions in these smaller names, historical data showing most stocks underperform cash argues for modest position sizing.
- Special Report: The company SpaceX cannot operate without
Big tech is wobbling. The Russell 2000 is not.
That split has sent investors hunting among smaller names for value the mega caps stopped offering months ago. James Early, who runs research at Curia Financial and models his stock-picking on Warren Buffett's approach to durable, cash-generating businesses, laid out three small-cap stocks trading under $10 a share. Each is profitable and built on fundamentals rather than hype.
[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker included (Ad)
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.
Mega-cap tech's loss has become small-cap America's gain, and these three names show why.
Part of the appeal of a sub-$10 stock is simple math: a few hundred dollars buys many more shares than it would in a $200 name. Fractional shares have made that distinction less important than it used to be, but Early's advice still holds: don't anchor too much on price alone. What matters is whether the business underneath is worth owning.
Home Health Care Draws Insurer Interest
Aveanna Healthcare Holdings (NASDAQ: AVAH) provides in-home care for complex and expensive patient cases, with Medicare and Medicaid making up roughly 91% of revenue. Home-based care costs a fraction of hospital monitoring, and insurers have taken notice.
Aveanna Healthcare delivered 16% revenue growth over the past year and raised its guidance twice, evidence that demand is outrunning even management's expectations. The company operates across dozens of U.S. states.
Early sees this as a potential buyout target rather than a moonshot. At a roughly $2 billion market cap, a larger insurer, home health platform, or private equity firm could easily absorb it. The stock has already climbed more than 120% over the past year, but Early argues that run-up matters less for a company this small: institutions can't buy in size without moving the price, which leaves room for retail investors to get in before Wall Street can.
Healthcare overall has lagged its potential in recent years, overshadowed by AI enthusiasm. But roughly 18% to 19% of U.S. GDP flows through healthcare spending, and an aging population isn't a trend that quickly reverses. That demand tends to hold up even in a downturn, since medical care is one budget line people don't cut.
An Ugly Legacy Business Funds a Clean One
Genworth Financial (NYSE: GNW) splits into two very different businesses.
The first is its roughly 82% stake in Enact Holdings (NASDAQ: ACT), which sells private mortgage insurance in a market growing about 8% annually. That segment runs at a 55% net profit margin, funding the second bucket: a closed book of long-term care policies written decades ago and badly underpriced, still costing the company $300 million to $400 million a year.
That drag is finite. Genworth trades at roughly 17 times earnings, below the S&P 500 average, and the stock has climbed steadily over the past five years as the Enact business has carried the load. Early is drawn to exactly this kind of complexity: a company that looks messier from the outside than it performs on the inside.
Growth here won't be explosive. Early expects something closer to 10% to 12% annually, tracking a mortgage insurance market that grows faster than GDP but isn't reinventing itself. What Genworth has demonstrated, through both rising and falling rate environments, is that the pivot already worked. The stock hasn't moved much with rate swings, and Early argues a softer rate environment ahead, with more housing inventory, could help rather than hurt.
A 1990s Survivor Bets on AI
eGain Corporation (NASDAQ: EGAN) has been around since 1997. Founded by Ashu Roy, the customer relationship management software company went public in 1999, then lost nearly all its value before a reverse split kept it listed. It has quietly stayed profitable for decades on $80 million to $90 million in annual revenue.
Now eGain is repositioning itself as an AI customer service platform, and early data is notable: non-AI customer retention is around 101%, while AI-driven retention is near 116%. Clients include the IRS, JPMorgan Chase & Co (NYSE: JPM), and other large enterprises.
The stock has fallen from roughly $15 a year ago to the mid-single digits, tracking the broader software sell-off as the market debates whether AI helps or hurts software companies. Early argues the labor-intensive nature of customer service makes AI a net positive here, not a threat, and that eGain's three-decade profitable base offers a floor even if the AI bet takes time to play out. He's still clear-eyed about the risk: this is a micro-cap that can swing sharply for no obvious reason, and he keeps positions like it small, often under 1% of a portfolio.
The Risk and the Upside
The upside in small caps and micro caps is real: institutions largely can't compete for shares, leaving retail investors an edge that mostly disappears once a company gets bigger. The risk is real, too, and it's larger than most investors assume. Research from Arizona State University professor Hendrik Bessembinder, covering nearly a century of U.S. stock market data, found that just 4% of publicly traded companies accounted for all of the market's net wealth creation above cash returns. The rest, collectively, did no better than holding Treasury bills.
That's the case for keeping any single small-cap bet modest, no matter how strong the story. Stay disciplined on position size, because that's what determines whether a good idea turns into a good outcome.
Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This email content is a sponsored email sent on behalf of American Market News, a third-party advertiser of DividendStocks.com and MarketBeat.
If you need help with your newsletter, please feel free to email our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl. #620, Sioux Falls, South Dakota 57103. United States..
Read More: Understanding what Trump just did (From Porter & Company)
This email content is a sponsored email sent on behalf of American Market News, a third-party advertiser of DividendStocks.com and MarketBeat.
If you need help with your newsletter, please feel free to email our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl. #620, Sioux Falls, South Dakota 57103. United States..
Subscribe to:
Posts (Atom)